First Trust Advisors LP Buys 1,675 Shares of Cencora, Inc. $COR

First Trust Advisors LP raised its stake in shares of Cencora, Inc. (NYSE:COR) by 0.3% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 653,744 shares of the company’s stock after buying an additional 1,675 shares during the quarter. First Trust Advisors LP owned about 0.34% of Cencora worth $205,367,000 at the end of the most recent quarter.

Several other hedge funds have also added to or reduced their stakes in COR. Vanguard Group Inc. increased its holdings in shares of Cencora by 0.9% during the fourth quarter. Vanguard Group Inc. now owns 23,617,117 shares of the company’s stock valued at $7,976,681,000 after acquiring an additional 221,570 shares in the last quarter. State Street Corp grew its position in Cencora by 1.3% during the 4th quarter. State Street Corp now owns 9,305,507 shares of the company’s stock valued at $3,142,935,000 after purchasing an additional 115,191 shares during the last quarter. T. Rowe Price Investment Management Inc. increased its stake in Cencora by 160.1% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 6,700,091 shares of the company’s stock valued at $2,262,956,000 after purchasing an additional 4,123,795 shares in the last quarter. Geode Capital Management LLC increased its stake in Cencora by 3.2% during the 4th quarter. Geode Capital Management LLC now owns 5,459,476 shares of the company’s stock valued at $1,843,268,000 after purchasing an additional 169,055 shares in the last quarter. Finally, JPMorgan Chase & Co. raised its holdings in Cencora by 6.5% in the fourth quarter. JPMorgan Chase & Co. now owns 4,982,557 shares of the company’s stock worth $1,682,859,000 after buying an additional 304,760 shares during the last quarter. 97.52% of the stock is owned by institutional investors.

Insider Buying and Selling at Cencora

In related news, Director Lauren M. Tyler bought 550 shares of the stock in a transaction that occurred on Monday, June 22nd. The shares were bought at an average cost of $270.23 per share, for a total transaction of $148,626.50. Following the completion of the transaction, the director owned 4,359 shares of the company’s stock, valued at approximately $1,177,932.57. This trade represents a 14.44% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 0.38% of the stock is owned by corporate insiders.

Cencora Price Performance

COR opened at $300.90 on Thursday. The company’s 50-day simple moving average is $282.60 and its two-hundred day simple moving average is $316.76. The company has a debt-to-equity ratio of 3.40, a quick ratio of 0.59 and a current ratio of 0.95. The stock has a market capitalization of $58.54 billion, a P/E ratio of 23.07, a P/E/G ratio of 1.68 and a beta of 0.58. Cencora, Inc. has a 52-week low of $244.82 and a 52-week high of $377.54.

Cencora (NYSE:COR) last announced its earnings results on Wednesday, May 6th. The company reported $4.75 earnings per share for the quarter, missing analysts’ consensus estimates of $4.82 by ($0.07). The company had revenue of $78.36 billion for the quarter, compared to analysts’ expectations of $81.09 billion. Cencora had a net margin of 0.78% and a return on equity of 135.20%. Cencora’s quarterly revenue was up 3.9% on a year-over-year basis. During the same quarter in the prior year, the firm posted $4.42 earnings per share. Cencora has set its FY 2026 guidance at 17.650-17.900 EPS. As a group, analysts predict that Cencora, Inc. will post 17.79 EPS for the current year.

Cencora declared that its board has authorized a share repurchase program on Thursday, May 21st that allows the company to repurchase $2.00 billion in shares. This repurchase authorization allows the company to reacquire up to 3.9% of its shares through open market purchases. Shares repurchase programs are typically an indication that the company’s leadership believes its stock is undervalued.

Cencora Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Monday, June 1st. Shareholders of record on Friday, May 15th were given a $0.60 dividend. The ex-dividend date was Friday, May 15th. This represents a $2.40 annualized dividend and a yield of 0.8%. Cencora’s dividend payout ratio (DPR) is presently 18.40%.

Analyst Ratings Changes

Several research analysts have recently issued reports on the stock. Robert W. Baird dropped their target price on shares of Cencora from $420.00 to $339.00 and set an “outperform” rating on the stock in a research note on Thursday, May 7th. Citigroup reduced their price target on shares of Cencora from $405.00 to $355.00 and set a “buy” rating for the company in a research report on Thursday, May 7th. Weiss Ratings lowered shares of Cencora from a “buy (b-)” rating to a “hold (c+)” rating in a report on Tuesday, June 30th. William Blair initiated coverage on Cencora in a research report on Tuesday, April 28th. They issued a “market perform” rating on the stock. Finally, Wells Fargo & Company cut their target price on Cencora from $429.00 to $331.00 and set an “overweight” rating on the stock in a research note on Monday, May 11th. Eleven analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $367.75.

Cencora Company Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.